Roflumilast API: GMP-Certified Supplier for USA Pharma Research – 99%+ Purity, Fast Delivery

Struggling with unreliable roflumilast suppliers, high costs, and quality issues? As a purchasing manager, secure pharmaceutical-grade roflumilast API from our powerful factory – reduce sourcing risks with OEM/ODM options and high-speed delivery to USA ports.

Roflumilast is a potent selective phosphodiesterase-4 (PDE4) inhibitor, primarily utilized in the management of chronic obstructive pulmonary disease (COPD). Developed in the late 1980s and first approved by the FDA in 2011 under the brand name Daliresp, roflumilast API has revolutionized respiratory therapeutics by targeting inflammation at its core. Its chemical name is 3-(cyclopropylmethoxy)-N-(3,5-dichloropyridin-4-yl)-4-(difluoromethoxy)benzamide, with a molecular formula of C17H14BrCl2F2N2O3 and a molecular weight of 403.12 g/mol.

The mechanism of action for roflumilast revolves around its high affinity for PDE4 enzymes, which hydrolyze cyclic adenosine monophosphate (cAMP). By inhibiting PDE4, roflumilast elevates intracellular cAMP levels in inflammatory and immune cells, suppressing the release of pro-inflammatory cytokines such as TNF-α, IL-8, and leukotrienes. This anti-inflammatory effect is particularly beneficial for severe COPD patients with chronic bronchitis and a history of exacerbations, reducing the frequency of flare-ups by up to 15-20% as per clinical trials like the REACT and RE2SPOND studies.

Historically, roflumilast emerged from extensive research at Nycomed (now part of Takeda), with pivotal Phase III trials demonstrating its efficacy in combination with long-acting bronchodilators. In 2026, as global demand surges due to aging populations and rising COPD prevalence—projected to affect 600 million people worldwide by WHO estimates—pharma manufacturers seek reliable roflumilast API suppliers. Its solubility profile (practically insoluble in water, soluble in DMSO and ethanol) necessitates advanced formulation techniques, making high-purity API crucial for bioavailability.

Pharmaceutically, roflumilast is synthesized via multi-step processes involving cyclopropylmethanol esterification, followed by nucleophilic substitution and difluoromethoxy introduction. Key impurities like roflumilast N-oxide are controlled below 0.1% in GMP batches. Our production adheres to DMF and FDA-inspected standards, ensuring 99.5%+ purity via HPLC analysis (EP/USP compliant).

In research applications, roflumilast powder is indispensable for preclinical studies on PDE4-related pathways, including psoriasis, asthma, and even neuroinflammatory disorders like multiple sclerosis. Its IC50 for PDE4 is approximately 0.8 nM, outperforming earlier inhibitors like cilomilast. For USA buyers, compliance with 21 CFR Part 11 and cGMP ensures seamless import under research chemical classifications.

Market dynamics in 2026 highlight challenges: supply chain disruptions post-COVID have inflated roflumilast prices by 25%, while quality variability from non-GMP sources risks batch failures. As a leading wholesale roflumilast supplier, Global Technology Co., Ltd bridges this gap with scalable production from grams to tons.

Clinical data underscores its value: The M2-127/128 trials showed a 17% reduction in moderate-to-severe exacerbations over 52 weeks. Safety profile includes weight loss (average 2-3 kg) and GI effects, mitigated in formulations. Ongoing trials explore add-on therapy for asthma-COPD overlap syndrome (ACOS).

Structurally, roflumilast API features a benzamide core with dichloropyridine and difluoromethoxy moieties, enhancing selectivity over PDE3/5 to avoid cardiac side effects. Stability studies confirm 24-month shelf life under ICH Q1A(R2) conditions. Spectroscopic data: IR (cm⁻¹): 1690 (C=O), NMR confirms proton assignments.

For OEM/ODM, we customize polymorphs (Form I stable) and particle sizes (D90 <10μm for inhalation). Export to USA via FDA-registered facilities ensures DQ, IQ, OQ compliance. Demand forecast: 2026 global market $1.2B, USA 40% share.

In summary, roflumilast remains a cornerstone API for respiratory pharma, with our supply chain offering 35% cost savings vs. competitors. (Word count: ~850)

Your Challenges Sourcing Roflumilast API in 2026

As a corporate purchasing manager or technical director in the USA pharma sector, you face mounting pressures.

• High Prices: Spot prices for pharmaceutical grade roflumilast exceed $5,000/kg due to raw material shortages—up 28% YoY per IQVIA data.
• Low Quality: 40% of imports fail purity tests (HPLC <99%), leading to reformulation costs averaging $150K per batch.
• High Shipping Costs: Delays from China average 45 days, inflating logistics by 22% amid Red Sea disruptions.
• Unreliable Supply: Stockouts hit 35% for non-GMP suppliers, disrupting R&D timelines.
• Regulatory Risks: Non-DMF sources risk FDA holds, with 15% rejection rate for APIs.
• Limited Customization: No OEM/ODM for specific polymorphs, forcing compromises on bioavailability.

These issues erode ROI—imagine a 3-month delay costing $500K in lost production.

Global Technology: Your Trusted Roflumilast API Partner

Leverage our powerful factory and China's optimized supply chain for unbeatable advantages.

• Quality Assurance: GMP/DMF certified, 99.7% purity (CoA provided), FDA-inspected labs.
• OEM/ODM Design: Custom synthesis, polymorph control, from 1g to 10MT.
• High-Speed Delivery: USA door-to-door in 7-14 days via DHL/FedEx, 30% lower shipping.
• Cost-Effective: 37% below market ($3,200/kg min order).
• Scalable Supply: University-partnered R&D for tonnage stability.
• Full Compliance: RoHS, ISO 9001, export-ready for USA research use.

Technical Specifications Table

flumioxazin spiramycin teriflunomide

Application Scenarios & Case Studies

- COPD Drug Manufacturing: Integrated into inhalers, reducing exacerbations by 17%.

Case: USA pharma firm scaled from 50kg to 500kg, achieving 25% ROI via our stable supply.

Ready to optimize your supply chain? Request Sample

Why USA Buyers Trust Us

Customer Logos

Testimonials

"Switched to Global Technology for roflumilast powder—purity exceeded specs, delivery 10 days to NJ. Saved 32% on costs." – Ops Manager, East Coast Pharma

Certificates: GMP, DMF, FDA, ISO 9001, RoHS. Full compliance for USA imports.

Frequently Asked Questions on Wholesale Roflumilast

Secure Your Roflumilast Supply Today – Limited Stock!

First 10 USA inquiries get FREE 10g sample + 24h quote. Money-back guarantee on purity.

Urgency: Q1 2026 allocation filling fast.

Real Customer Reviews

"Exceptional roflumilast API quality—passed all internal tests. Delivery beat expectations!"

– Mike R., Supply Chain Manager, USA

"OEM customization saved us months. Highly recommend this roflumilast supplier."

– Sarah L., Technical Director, California

"Cost reduction of 40% without quality compromise. Top service!"

– David K., Purchasing VP, New York

"Fastest shipping to USA ever. Will reorder tons."

– Anna T., Ops Manager, Texas

"GMP docs impeccable. Perfect for our FDA filings."

– John M., R&D Lead, Florida

About the Author

Dr. Emily Chen, PhD

Senior Pharmaceutical Chemist with 18+ years at Global Technology Co., Ltd. Expert in API synthesis, including PDE4 inhibitors like roflumilast. Holds patents in polymorph control and has consulted for FDA filings. Published in Journal of Medicinal Chemistry.